[1] Wallace MC, Preen D, Jeffrey GP, et al. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol, 2015,9: 765-779.
[2] George J, Patel T. Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis, 2015, 35: 63-74.
[3] Esteller M. Non-coding RNAs in human disease. Nat Rev Genet, 2011, 12:861-874.
[4] Shukla GC, Singh J, Barik S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol, 2011, 3:83-92.
[5] Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol, 2014, 9:287-314.
[6] Holland B, Wong J, Li M, et al. Identification of human microRNA-like sequences embedded within the protein-encoding genes of the human immunodeficiency virus. PLoS One, 2013, 8:e58586.
[7] Chu R, Mo G, Duan Z, et al. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal, 2014, 12:45.
[8] Fang Y, Xue JL, Shen Q, et al. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology, 2012, 55:1852-1862.
[9] Shen G, Jia H, Tai Q, et al. miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis, 2013, 34:211-219.
[10] Liu YR, Tang RX, Huang WT, et al. Long noncoding RNAs in hepatocellular carcinoma: Novel insights into their mechanism. World J Hepatol, 2015, 7:2781-2791.
[11] Liu WH, Yeh SH, Lu CC, et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology, 2009, 136:683-693.
[12] Zhang X, Zhang E, Ma Z, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology, 2011, 53:1476-1485.
[13] Elton TS, Selemon H, Elton SM, et al. Regulation of the MIR155 host gene in physiological and pathological processes. Gene, 2013, 532:1-12.
[14] Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res, 2012, 22:1775-1789.
[15] Takahashi K, Yan I, Haga H, et al. Long noncoding RNA in liver diseases. Hepatology, 2014, 60:744-753.
[16] Wang Z, Li X. The role of noncoding RNA in hepatocellular carcinoma. Gland Surg, 2013, 2:25-29.
[17] Lai MC, Yang Z, Zhou L, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol, 2012, 29:1810-1816.
[18] Ishibashi M, Kogo R, Shibata K, et al. Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. Oncol Rep, 2013, 29:946-950.
[19] Lv J, Yu YQ, Li SQ, et al. Aflatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1. Asian Pac J Cancer Prev, 2014, 15:2565-2570.
[20] Du Y, Kong G, You X, et al. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem, 2012, 287:26302-26311.
[21] Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol, 2012, 56:1371-1383.
[22] Lv Z, Wei Y, Wang D, et al. Argonaute 2 in cell-secreted microvesicles guides the function of secreted miRNAs in recipient cells. PLoS One, 2014, 9:e103599.
[23] Kogure T, Lin WL, Yan IK, et al. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology, 2011, 54:1237-1248.
[24] Diaz G, Melis M, Tice A, et al. Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer, 2013, 133:816-824.
[25] Fu Y, Wei X, Tang C, et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett, 2013, 6:1811-1815.
[26] Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell, 2011, 19:232-243.
[27] Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol, 2014, 31:984.
[28] Karakatsanis A, Papaconstantinou I, Gazouli M, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog, 2013, 52:297-303.
[29] Xie K, Liu J, Zhu L, et al. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol, 2013, 37:998-1002.
[30] Son MS, Jang MJ, Jeon YJ, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene, 2013, 524:156-160.
[31] Cheetham SW, Gruhl F, Mattick JS, et al. Long noncoding RNAs and the genetics of cancer. Br J Cancer, 2013, 108:2419-2425.
[32] Chen Z, Ma T, Huang C, et al. MicroRNA-148a: a potential therapeutic target for cancer. Gene, 2014, 533:456-457.
[33] Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer, 2010, 103:1617-1626.
[34] Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology, 2013, 57:840-847.
[35] Park JK, Kogure T, Nuovo GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res, 2011, 71:7608-7616.
[36] Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, 2010, 327:198-201.
[37] Tay FC, Lim JK, Zhu H, et al. Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Adv Drug Deliv Rev, 2015, 81:117-127. |
